Clinical Trial Update: Assessment of V0018 2.5 mg Effect on Craving [Phase 2]

View source ↗

Summary

Phase 2 trial of V0018 at 2.5 mg completed to assess craving reduction in healthy highly dependent smokers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tobacco Use Disorder

Drugs mentioned

• V0018

Snippet

Sponsor: Pierre Fabre Medicament | Conditions: Healthy Highly Dependant Smokers | Phase 2 | Status: COMPLETED